MONTREAL, April 17, 2026 /CNW/ -- Bracco Imaging, a global leader in diagnostic imaging, today announced that Health Canada approved VUEWAY (R) injection (gadopiclenol), a macrocyclic gadolinium-based ...
Contrast materials can help highlight areas of interest in MRI scans. Contrast injections may cause side effects like mild rashes and hives, but, in rare instances, it is also possible for a person to ...
CHALFONT ST GILES, England--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) has approved Clariscan™, a macrocyclic, ionic, gadolinium-based, MRI contrast agent, expanding the GE ...
LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today it has launched Gadoterate Meglumine Injection, USP, a bioequivalent and therapeutic equivalent substitute for the contrast agent ...
Elucirem™ has the highest relaxivity compared to other non-specific GBCAs (gadolinium-based contrast agents) 1 Elucirem™ requires only half the gadolinium dose of conventional non-specific GBCAs, ...
VUEWAY injection is highly stable and shows the highest relaxivity among gadolinium-based contrast agents available for clinical use i VUEWAY injection is approved for use in adult and pediatric ...
PRINCETON, N.J., Nov. 11, 2024 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, is proud to announce ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results